Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma
Hamza Hashmi, Abu‐Sayeef Mirza, Alicia Darwin, Constantine Logothetis, Franco Garcia, Anuhya Kommalapati, Rahul Mhaskar, Christina A. Bachmeier, Julio C. Chávez, Bijal Shah, Javier Pinilla‐Ibarz, Farhad Khimani, Aleksandr Lazaryan, Hien Liu, Marco L. Davila, Frederick L. Locke, Taiga Nishihori, Michael D. Jain
Abstract
Key Points VTE developed in 11% of lymphoma patients after CAR T-cell therapy and was managed safely with anticoagulation. Coagulation abnormalities after CAR T-cell therapy occur but do not commonly lead to bleeding events.
Topics & Concepts
LymphomaMedicineCAR T-cell therapyCD19Cell therapyVenous thromboembolismInternal medicineCellImmunologyOncologyChimeric antigen receptorCancerImmunotherapyAntigenThrombosisBiologyGeneticsCAR-T cell therapy researchVirus-based gene therapy researchLymphoma Diagnosis and Treatment